Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) alone and when co-administered with humanized Anti-CD19 Chimeric Antigen Receptor Redirected T cells (huCART19) In Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Age: Between 0 - 99 Years
Gender: Male or Female
Recruitment StatusEnrolling By Invitation
If you need assistance finding a non-cancer study or if you have any questions, please email firstname.lastname@example.org